Full Press Release Details
BridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine.
BBIO
BridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine
Key Takeaway: BridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine
Price reaction · baseline $39.73 (2024-01-09 close) · hit after-hours · clean, no other BBIO news in the window
day 0 close · peak
+0.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis